GNH USA

Europe — EMA

Immitis

GNH USA supplies Immitis (Rivastigmine Hydrogen Tartrate), a cholinesterase inhibitor for Alzheimer’s disease and Parkinson’s disease dementia.

Rivastigmine Hydrogen Tartrate

Request sourcing

1
Pack/s

What is Rivastigmine Hydrogen Tartrate?

Rivastigmine hydrogen tartrate, the active ingredient in Immitis, is a cholinesterase inhibitor presented as an oral formulation for oral use. It is employed in the management of cognitive decline associated with Alzheimer’s disease and Parkinson’s disease dementia, targeting adult patients who require symptomatic treatment.

GNH USA supplies Immitis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Rivastigmine Hydrogen Tartrate used for?

Immitis is a cholinesterase inhibitor used to address cognitive impairment in neurodegenerative disease conditions.

Alzheimer’s disease (mild to moderate): improves cognition and daily functioning in patients with Alzheimer’s disease. Parkinson’s disease dementia: mitigates cognitive symptoms in patients with dementia secondary to Parkinson’s disease. Cognitive decline in neurodegenerative disorders: provides symptomatic relief of memory and attention deficits.

What are the side effects of Rivastigmine Hydrogen Tartrate?

Common Side Effects: - Nausea: upset stomach that may occur after dosing. - Vomiting: occasional expulsion of stomach contents. - Diarrhea: loose stools, often mild to moderate. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Severe bradycardia: markedly slow heart rate that can cause dizziness or fainting. - Gastrointestinal bleeding: risk increased when combined with anticoagulants or NSAIDs. - Hepatic dysfunction: abnormal liver enzymes or liver injury.

What precautions apply to Rivastigmine Hydrogen Tartrate?

Immitis requires careful clinical monitoring and individualized dosing. - Dose titration: start low and increase gradually as tolerated. - Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic impairment: use with caution in liver disease. - Cardiovascular disease: monitor heart rate and rhythm. - Concomitant anticholinergic drugs: avoid or limit use to prevent reduced efficacy. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

What does Rivastigmine Hydrogen Tartrate interact with?

Immitis may interact with several medication classes.

Major Interactions (Avoid): - Anticholinergic agents: may diminish therapeutic effect. - Beta‑blockers: can exacerbate bradycardia. - Other cholinesterase inhibitors: risk additive cholinergic toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: increase risk of gastrointestinal bleeding. - Anticoagulants: may enhance bleeding tendency. - CYP3A4 inhibitors: may raise rivastigmine plasma levels.

Frequently asked questions

What is Immitis used for?+
Immitis contains rivastigmine hydrogen tartrate, a cholinesterase inhibitor indicated for symptomatic treatment of cognitive decline in Alzheimer’s disease and Parkinson’s disease dementia. It is prescribed for adult patients with mild to moderate disease to improve cognition, daily functioning, and behavior. The medication does not cure the underlying neurodegenerative process but may provide measurable benefit in approved indications.
How does rivastigmine hydrogen tartrate work?+
Rivastigmine hydrogen tartrate reversibly inhibits both acetylcholinesterase and butyrylcholinesterase enzymes in the central nervous system. By blocking these enzymes, it slows the breakdown of acetylcholine, increasing its concentration at synaptic clefts. The enhanced cholinergic neurotransmission helps to compensate for the loss of cholinergic neurons that occurs in Alzheimer’s disease and Parkinson’s disease dementia, thereby improving cognitive function.
What is the usual dose of Immitis?+
The specific dose of Immitis is determined by the prescribing clinician based on the patient’s clinical status, tolerability, and response to therapy. Typically, treatment is initiated at a low dose and titrated upward at regular intervals, but the exact regimen, including tablet strength and frequency, must be individualized and documented in the prescription. Patients should follow the prescriber’s instructions and not adjust the dose on their own.
Is Immitis safe during pregnancy or breastfeeding?+
Safety data for rivastigmine hydrogen tartrate in pregnancy and lactation are limited. The drug is generally classified as contraindicated or used only when the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider before initiating therapy.
How do I order Immitis from GNH USA?+
To request Immitis, visit the product page on gnh-usa.com, enter the required quantity, and submit the enquiry form. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The sales team will then respond with pricing, availability, shipping details—including any temperature‑controlled logistics if needed—and assistance with import documentation.
How does Immitis compare with other dementia drugs?+
Immitis (rivastigmine) belongs to the cholinesterase inhibitor class, similar to donepezil and galantamine. Compared with these agents, rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, which may offer broader cholinergic enhancement. Its oral formulation is often used when patients experience inadequate response or intolerance to other inhibitors, though it may be associated with a higher incidence of gastrointestinal side effects. Choice of therapy depends on individual patient factors, tolerability, and clinician judgment.
How should Immitis be stored and handled?+
Immitis should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging to protect it from moisture, light, and excessive heat. Do not store in bathrooms or near kitchen appliances. If the product is a tablet, ensure the container remains tightly closed. Dispose of any unused medication according to local regulations or return it to a pharmacy for proper disposal.
How is Immitis administered?+
Immitis is taken orally, usually with food to lessen gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not chewed, crushed, or split unless specifically instructed by a healthcare professional. Dosing schedules are typically once or twice daily, depending on the prescribed regimen. Patients should adhere to the timing recommended by their prescriber and maintain consistent administration times to achieve stable drug levels.
What are the most serious risks associated with Immitis?+
The most serious risks of Immitis include severe bradycardia, which can lead to fainting or heart block, and gastrointestinal bleeding, especially in patients taking anticoagulants or NSAIDs. Hepatic dysfunction may also occur, requiring monitoring of liver enzymes. Rare but severe reactions such as cholinergic crisis, seizures, or serious skin reactions (e.g., Stevens‑Johnson syndrome) demand immediate medical attention. Patients should be educated to report any concerning symptoms promptly.
Who should not use Immitis?+
Immitis is contraindicated in patients with known hypersensitivity to rivastigmine or any of its excipients. It should be avoided in individuals with severe hepatic impairment, active peptic ulcer disease, or uncontrolled asthma, as cholinergic stimulation may exacerbate these conditions. Patients taking other cholinesterase inhibitors or high‑dose anticholinergic medications should not use Immitis without specialist guidance. Pregnant or breastfeeding women should only use the drug when clearly indicated and after thorough risk‑benefit assessment by their clinician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Rivastigmine Hydrogen Tartrate
Route
Oral Use
Manufacturer
Lavipharm S.A
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU